NCT03697577
Breast Cancer Type: HR+ & HER2-negative
Hormone Mutations: ER+
Other Mutations:
Breast Cancer Tissue:
Recruitment Status: Recruiting
Drug Category: Serine-Threonine Kinase Inhibitor
Key Eligibility Criteria:
Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases:
Additional Notes:
Exclusions: Patients with prior CDK 4/6 use in any setting; Patients with untreated unstable brain metastasis that do not require treatment – see trial for details
https://ClinicalTrials.gov/show/NCT03697577